Professor Li Zhang is a renowned medical oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University. With over 30 years, he has held progressive roles at SYSUCC, serving as an attending physician, associate professor, and currently as a full professor in the Department of Medical Oncology at SUSYCC. Now, he is an active member of leading professional societies, including ASCO, AACR, ESMO, CSCO, CACA, IASLC, and MASCC. Dr. Zhang is also a senior consultant for the Center of Drug Evaluation (CDE) under the Chinese Food and Drug Administration (CFDA). Notably, he was a principal contributor to the drafting of the CFDA Guidance for Industry: Clinical Trials for the Approval of Cancer Drugs and Biologics (Second Version, 2006). His expertise and contributions have been instrumental in shaping regulatory frameworks for cancer drug development in China.

Professor Zhang’s research interest is in the development of molecular, prognostic and therapeutic approaches to improve the care for patients with lung cancer and Nasopharyngeal carcinoma. He is also actively involved in cancer palliative and supportive care like cancer pain management and chemotherapy induced nausea and vomiting (CINV). He contributes extensively to the Chinese Anti-Cancer Association (CACA) where he currently serves as Vice-President of Small Cell Lung Cancer Committee; President of Clinical Trial Committee, CACA. He is also a standing committee member of the Chinese Society of Clinical Oncology (CSCO) and President of immunotherapy expert committee of CSCO; Vice-President of NSCLC Expert Committee and Vice-President of Supportive Care Expert Committee of CSCO.

Professor Zhang has published more than 400 peer review research papers in top-tier journals like: Lancet, Lancet Oncology, Lancet Respiratory Medicine, JAMA, JAMA Oncology, Nature Medicine, Nature Communications, Cancer Cell, Journal of Clinical Oncology, Annals of Oncology. He also presented abstracts to many major congresses like ASCO, WCLC, ESMO, MASCC meetings.  He is an editorial board member of Clinical Lung Cancer, Chinese Journal of Clinical Oncology, Cancer Communication.

1. Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial.  W Fang, Y Zhao, Y Luo, R Yang, Y Huang, Z He, H Zhao, M Li, K Li, Q Song, X Du, Y Sun, W Li, F Xu, Z Wang, K Yang, Y Fan, B Liu, H Zhao, Y Hu, L Jia, S Xu, T Yi, D Lv, H Lan, M Li, W Liang, Y Wang, H Yang, Y Jia, Y Chen, J Lu, J Feng, C Liu, M Zhou, J Zhou, X Liu, N Zhou, M He, X Dong, H Chen, Y Chen, H Su, X Li, Z Zhang, L Yang, Y Cheng, L Chen, X Hou, Y Zhang, J Guo, Z Wang, H Lu, D Wu, W Feng, W Li, J Huang, Y Wang, X Song, J Peng, L Liu, Y Guo, W Li, D Lu, M Hu, Z Wang, B Li, M Xia, Li Zhang.     JAMA 2024; Vol 332(7):561-570

2. ALESIA: a randomised phase 3 study of alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. C Zhou, S Kim, T Reungwetwattana, J Zhou, Y Zhang, J He, J Yang, Y Cheng, S Lee, L Bu, T Xu, L Yang, C Wang, T Liu, P N. Morcos, Y Lu, Li Zhang.    The Lancet Respiratory Medicine 2019

3. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.    S Hong, Y Zhang, G Yu, P Peng, J Peng, J Jia, X Wu, Y Huang, Y Yang, Q Lin, X Xi, M Xu, D Chen, X Lu, R Wang, X Cao, X Chen, Z Lin, J Xiong, Q Lin, C Xie, Z Li, J Pan, J Li, S Wu, Y Lian, Q Yang, C Zhao, W Fang, Li Zhang.   Journal of Clinical Oncology 2021; Vol 39(29):3273-3282

4. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Y Yang, S Qu, J Li, C Hu, M Xu, W Li, T Zhou, L Shen, H Wu, J Lang, G Hu, Z Luo, Z Fu, S Qu, W Feng, X Chen, S Lin, W Zhang, X Li, Y Sun, Z Lin, Q Lin, F Lei, J Long, J Hong, X Huang, L Zeng, P Wang, X He, B Zhang, Q Yang, X Zhang, J Zou, W Fang, Li Zhang:  Lancet Oncology 2021; Vol 22(8):1162-1174

5. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.  Y Yang, J Zhou, J Zhou, J Feng, W Zhuang, J Chen, J Zhao, W Zhong, Y Zhao, Y Zhang, Y Song, Y Hu, Z Yu, Y Gong, Y Chen, F Ye, S Zhang, L Cao, Y Fan, G Wu, Y Guo, C Zhou, K Ma, J Fang, W Feng, Y Liu, Z Zheng, G Li, N Wu, W Song, X Liu, S Zhao, L Ding, L Mao, G Selvaggi, X Yuan, Y Fu, T Wang, S Xiao, Li Zhang   Lancet Respiratory Medicine 2020; Vol 8(1):45-53

6. Gemcitabine plus cisplatin versus fl uorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.   Li Zhang, Y Huang, S Hong, Y Yang, G Yu, J Jia, P Peng, X Wu, Q Lin, X Xi, J Peng, M Xu, D Chen, X Lu, R Wang, X Cao, X Chen, Z Lin, J Xiong, Q Lin, C Xie, Z Li, J Pan, J Li, S Wu, Y Lian, Q Yang, C Zhao:  The Lancet 2016; Vol 388(10054):1883-1892